Xeris Biopharma Holdings (XERS) Amortization of Deferred Charges (2020 - 2026)

Xeris Biopharma Holdings has reported Amortization of Deferred Charges for 7 years, with the latest figure at $900000.0 in Q1 2026.

• For the quarter ending Q1 2026, Amortization of Deferred Charges rose 12.5% year-over-year to $900000.0; the trailing twelve-month figure through Mar 2026 stood at $3.4 million (up 5.19% YoY), and the FY2025 full-year result was $3.4 million, up 12.43% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $900000.0, up from $866000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $900000.0 in Q1 2026, with the low at $219000.0 in Q1 2022.
• Historically, Amortization of Deferred Charges has averaged $641529.4 across 5 years, with a median of $600000.0 in 2023.
• The largest YoY upside for Amortization of Deferred Charges was 150.0% in 2022 against a maximum downside of 12.75% in 2022.
• Xeris Biopharma Holdings' Amortization of Deferred Charges stood at $448000.0 in 2022, then increased by 11.61% to $500000.0 in 2023, then soared by 60.0% to $800000.0 in 2024, then increased by 8.25% to $866000.0 in 2025, then advanced by 3.93% to $900000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $900000.0 (Q1 2026), $866000.0 (Q4 2025), and $800000.0 (Q3 2025), per Business Quant data.